Why FDA Boosters Authorization Could Be More Important for Pfizer and Moderna Than You Might Think
The third time's the charm. That's what the U.S. Food and Drug Administration (FDA) thinks could be the case with messenger RNA (mRNA) COVID-19 vaccines developed by Pfizer (NYSE: PFE), along with its partner BioNTech (NASDAQ: BNTX), and Moderna (NASDAQ: MRNA).
Last week, the FDA granted Emergency Use Authorization (EUA) for boosters of the two mRNA vaccines for all adults ages 18 and older. Previously, the agency had authorized boosters only for ages 65 and up, individuals who are at high risk of developing severe COVID-19, or those who work in especially risky environments. Now, any adult who has received the original two-dose regimen of the Pfizer-BioNTech or Moderna vaccines can get a third booster shot six months after their second dose.
Based on the immediate moves of these vaccine stocks, it might seem that the authorization of boosters really isn't all that big of a deal. But here's why the FDA's boosters authorization could be more important for Pfizer and Moderna than you might think.
Source Fool.com
